UBS O'Connor’s Y-mAbs Therapeutics YMAB Stock Holding History

UBS O'Connor’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-44,000	Closed	-$634K	–	345
2022 Q3	$634K	Buy	+44,000	New	+$729K	0.01%	790

Other funds holding YMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS O'Connor's YMAB Position: Q4 2022 in Review

UBS O'Connor sold out of Y-mAbs Therapeutics (YMAB) in Q4 2022, closing a stake of 44,000 shares — an estimated $634K sold.

UBS O'Connor first reported a position in YMAB in Q3 2022 and held it in 1 quarter. The position peaked at $634K in Q3 2022. 91 funds tracked by Wall St. Rank hold YMAB as of Q4 2022.

UBS O'Connor reported no remaining Y-mAbs Therapeutics position as of Q4 2022 after selling out during the quarter.
UBS O'Connor sold 44,000 Y-mAbs Therapeutics shares in Q4 2022, an estimated $634K.
UBS O'Connor first reported a position in Y-mAbs Therapeutics in Q3 2022 and held it in 1 quarter.
UBS O'Connor's Y-mAbs Therapeutics position peaked at $634K in Q3 2022.
91 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2022.

Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.